Patients with low‐risk MDS exhibit an ido/tph1 enzyme activity imbalance which regulates tryptophan by indoleamine 2,3‐dioxygenase (IDO) and tryptophan 2,3‐dioxygenase (TDO).21 The gene discussed is TDO2; the disease is myelodysplastic syndrome.